StocksDiva Bio Bin

[ManicTrader]

2 BOUNCE Plays to Watch. Experienced Traders Only. ZANE and HNSN

News out this morning and the pendulum is in motion. I will look to slide in long at the bottom after sell off.

HNSN Hansen Medical issues downside revenue guidance for Q1 (2.40 )

Co issues downside guidance for Q1 (Mar), sees Q1 (Mar) revs of $2.5-2.7 mln vs. $6.03 mln Thomson Reuters consensus. Co ships seven Sensei Robotic Catheter Systems in the later part of the quarter with an average sales price of approx $690,000. The co has received payment for one of the seven systems shipped in the first quarter and payments on the remaining six systems are due during the second quarter. Consistent with revenue recognition policies, revenue will be recognized on these seven systems as they are installed and physicians are trained, which the co expects will occur during 2010. Revenues for the quarter are expected to include recognition of revenue for one Sensei system previously deferred from a prior period and for the shipment of 624 Artisan catheters at an average sales price of approx $1,660. The expected range and components of 1Q10 revenues are estimates and are subject to change. The co shipped seven Sensei systems in Q110 compared to six Sensei systems in 4Q09. The co shipped approx 624 Artisan catheters in Q110 compared to 539 catheters in 4Q09.
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>

ZANE Zanett discloses update to Term Debt -- Convertible Debt Exchange Agreement (3.27 )

Co disclosed that on March 31, 2010, it entered into a Term Debt -- Convertible Debt Exchange Agreement with Rockport Investments pursuant to which the Company issued to a promissory note, convertible into common stock in the aggregate principal amount of $7,131,983. Co issued issue the Convertible Note in exchange for two promissory notes aggregating $5,325,000 and a line of credit to extend to the Company up to $3,000,000all currently held by the Investor and which matured on March 31, 2010 (extended from March 15, 2010 pursuant to the terms of the Exchange Agreement)... The initial conversion price of the principal and any accrued but unpaid interest on the Convertible Note is $2.08 per share (representing the closing bid price of the Common Stock immediately preceding the issuance of the Convertible Note), but the Investor, may, at its option, reset the conversion price once per calendar year to the greater of (a) the average of the closing sales price of the Common Stock during the preceding 20 consecutive trading day period and (b) $0.10. The conversion price is also subject to adjustment in the event of dilutive issuances by the Company or the Company's issuance of options, warrants or other rights to purchase Common Stock or convertible securities (subject to certain exceptions, including the grant of options to purchase Common Stock to employees, officers, directors or consultants of the Company).